FLGT: Revenue rose 4% year-over-year, but guidance was lowered due to billing transition impacts
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions and innovation in AI and pathology, but margins and guidance were impacted by billing system transition and lower collection rates. Full-year revenue guidance was revised down to $330–$340 million.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue grew 4% year-over-year to $85.4 million, driven by acquisitions and innovation in AI and pathology, but margins and guidance were impacted by billing system transition and lower collection rates. Full-year revenue guidance was revised down to $330–$340 million.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.